<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13281">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915407</url>
  </required_header>
  <id_info>
    <org_study_id>AGD 051</org_study_id>
    <nct_id>NCT01915407</nct_id>
  </id_info>
  <brief_title>AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction</brief_title>
  <official_title>AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aggredyne, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aggredyne, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the AggreGuide A-100 AA Assay's effectiveness for detecting aspirin induced platelet
      dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Platelet Activity Index (PAI) before and after ingestion of aspirin</measure>
    <time_frame>2 - 30 hours post aspirin ingestion</time_frame>
    <safety_issue>No</safety_issue>
    <description>PAI is the proprietary reporting unit of the Aggreguide.  It is related to the amount of platelet aggregation in the sample of whole blood.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Platelet Dysfunction Due to Aspirin Ingestion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        aspirin na√Øve subjects over 18
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18

        Exclusion Criteria:

          -  on aspirin in prior week

          -  medical history of platelet disorders

          -  contraindications to aspirin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aggredyne, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Platelet Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
